Y-mAbs Therapeutics YMAB 深 沪
已收盘 09-16 16:00:00 美东时间
8.61
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 8.61
- 总市值 39.00万
- 52周最高 16.11
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.55
- 委 比 0.00%
- 总股本 4.53万
- 历史最高 55.215
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.70
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多药物受理最新动态：Y-mAbs Therapeutics, Inc.那西妥单抗注射液补充申请获受理
国家药品监督管理局药品审评中心数据显示，2026年10月8日，Y-mAbs Therapeutics, Inc.的那西妥单抗注射液申请已获受理，受理号为JYS...
10-08 17:15
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Entera Bio Ltd. announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. With over 35 years of experience in global commercial leadership, Hamill joins Entera as it advances its late-stage clinical trials and prepares for the commercialization of EB613, an oral therapy for osteoporosis. Hamill previously served at Gilead Sciences and Amgen, leading multi-billion dollar franchises. Her expertise is expected ...
10-06 12:00
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
PMV Pharmaceuticals appoints Philip Herman as Chief Commercial Officer to lead commercial strategy and launch preparation for rezatapopt, a first-in-class p53 reactivator. The company plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer patients in Q1 2027. Herman brings over 24 years of experience in oncology and rare disease therapies, previously leading launches at Repare Therapeutics an...
09-08 12:00
Telix Appoints David Gill as Non-Executive Director
<p>Telix Pharmaceuticals Limited has appointed David Gill as a Non-Executive Director, effective May 11, 2026, with plans for him to become Chair in the future. Mr. Gill, a seasoned executive with over 35 years of experience in finance and leadership roles, brings expertise in capital markets, business scaling, and corporate strategy. Telix, a global biopharmaceutical company focused on radiopharmaceuticals, aims to strengthen its board as it con...
04-01 23:53
Y-Mabs Therapeutics Completes Merger with Perseus BidCo
Y-Mabs Therapeutics ( ($YMAB) ) has issued an announcement. On September 16, 20...
2025-09-16 21:20
Earnings Scheduled For August 8, 2025
Companies Reporting Before The Bell • BeOne Medicines (NASDAQ:ONC) is expected ...
2025-08-08 16:32
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a biopharmaceutical company focused on antibody-based therapies for cancer, announced it will report second quarter 2025 results before the market open on August 8, 2025. Due to the previously announced transaction with affiliated entities of SERB Pharmaceuticals, the company will not host an earnings conference call. Y-mAbs specializes in novel radioimmunotherapy and antibody-based cancer products, with ...
2025-08-07 11:30
美股牛股 | 创新药企YMAB单日翻倍！华米科技再升38%，近一个月涨幅超770%
创新药企YMAB单日翻倍！获SERB制药宣布全现金收购；华米科技隔夜再升38%，Q2业绩显著提升，近一个月累涨超770%>>
2025-08-06 17:04
